The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer

By Shi Yi-kang   Li Zhong-hua   Han Xi-qian   Yi Ji-hu   Wang Zhen-hua   Hou Jing-li   Feng Cong-ran   Fang Qing-hong   Wang Hui-hui   Zhang Peng-fei   Wang Feng-shan   Shen Jie   Wang Peng  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1131-1140

Springer Publishing Company

Access to resources Recommend Favorite

Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells

By          

Molecular Medicine Reports, Vol. 11, Iss. 4, 2015-01 ,pp. : 2908-2912

Spandidos Publications

Access to resources Recommend Favorite

Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer

By            

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 435-441

Spandidos Publications

Access to resources Recommend Favorite

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells

By                      

Oncology Reports, Vol. 27, Iss. 1, 2012-01 ,pp. : 10-16

Spandidos Publications

Access to resources Recommend Favorite

Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S 2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients

By Hsieh Yi-Hsuan  

Carcinogenesis, Vol. 34, Iss. 2, 2013-02 ,pp. : 475-485

Oxford University Press

Access to resources Recommend Favorite